Russell Investments Group Ltd. Sells 68,158 Shares of Insmed, Inc. $INSM

Russell Investments Group Ltd. decreased its holdings in Insmed, Inc. (NASDAQ:INSM) by 29.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 166,459 shares of the biopharmaceutical company’s stock after selling 68,158 shares during the period. Russell Investments Group Ltd.’s holdings in Insmed were worth $23,972,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Natixis Advisors LLC boosted its holdings in shares of Insmed by 11.3% in the third quarter. Natixis Advisors LLC now owns 39,450 shares of the biopharmaceutical company’s stock worth $5,681,000 after acquiring an additional 3,991 shares during the period. First Trust Advisors LP boosted its position in shares of Insmed by 407.8% during the 3rd quarter. First Trust Advisors LP now owns 240,646 shares of the biopharmaceutical company’s stock valued at $34,655,000 after acquiring an additional 193,254 shares during the last quarter. Neuberger Berman Group LLC raised its position in shares of Insmed by 1,277.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 150,106 shares of the biopharmaceutical company’s stock valued at $21,617,000 after buying an additional 139,211 shares in the last quarter. Gabelli Funds LLC purchased a new position in shares of Insmed in the 3rd quarter worth about $207,000. Finally, Crossmark Global Holdings Inc. purchased a new stake in Insmed in the third quarter worth approximately $316,000.

Insider Buying and Selling at Insmed

In other Insmed news, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00. Following the transaction, the chief executive officer owned 306,891 shares in the company, valued at $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total value of $15,293,208.00. Following the sale, the insider owned 41,754 shares of the company’s stock, valued at approximately $7,315,300.80. This represents a 67.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 189,651 shares of company stock valued at $31,784,545. Corporate insiders own 3.00% of the company’s stock.

Insmed Trading Up 0.1%

Shares of INSM opened at $139.52 on Friday. The company has a 50-day moving average of $155.93 and a 200 day moving average of $165.62. The firm has a market capitalization of $30.07 billion, a price-to-earnings ratio of -21.77 and a beta of 1.13. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. During the same quarter in the prior year, the company posted ($1.32) earnings per share. Insmed’s quarterly revenue was up 152.6% compared to the same quarter last year. On average, research analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of recent research reports. Leerink Partners reissued an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Wolfe Research set a $167.00 target price on shares of Insmed and gave the company an “outperform” rating in a research note on Thursday, December 18th. Mizuho dropped their target price on shares of Insmed from $211.00 to $204.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 24th. Morgan Stanley set a $166.00 price objective on Insmed in a report on Friday, February 20th. Finally, Cantor Fitzgerald upped their price target on Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $207.52.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.